Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition - Next-Generation Neuroimaging for Alzheimer’s Disease: From Molecules to Networks

Next-Generation Neuroimaging for Alzheimer’s Disease: From Molecules to Networks

Oral

Neuro A

Thursday, 14 May 2026

Ballroom West

16:00 - 17:50

Moderators: Xingfeng Shao & Qiuting Wen

Session Number: 605-03

CME/CE Credit Available

Similar Sessions

This session highlights cutting‑edge MRI and PET-MRI approaches to Alzheimer’s disease, spanning molecular pathology, cerebral blood flow, metabolism, myelin, iron, and neuroinflammation. Together, these studies advance biomarkers and predictive models that illuminate disease progression, resilience, and clinically actionable imaging across the Alzheimer’s spectrum.

Skill Level: Intermediate

16:00		605-03-001. Back to the Future: Predicting Individual Tau Progression in Alzheimer's Disease Robin Sandell, Kamalini Ranasinghe, Srikantan Nagarajan, Ashish Raj University of California San Francisco, San Francisco, United States of America Impact: A novel computational framework enables clinicians to forecast individual tau progression from single MRI/PET visits, facilitating personalized treatment planning and clinical trial stratification. Predicting future pathology patterns from baseline scans could transform precision medicine approaches in neurodegenerative disease management.
16:11		605-03-002. Improving Amyloid Detection and Brain PET Image Quality Using MR-Guided Reconstruction on Integrated PET/MR Yu Cai, Chen Lin, Manoj Jain, Robert Pooley, Jun Zhang, Brittany Benson, Matthew Spangler-Bickell, Alex Smith, Vivek Gupta, Catherine Bullock, Erik Middlebrooks, Neetu Soni Zhongda Hospital, School of Medicine, Southeast University, China Impact: MR-guided PET reconstruction enhances reader consistency, confidence, and diagnostic performance in amyloid PET/MR. This technique provides a reliable framework for amyloid PET diagnosis, potentially improving early detection and supporting the monitoring of anti-amyloid therapies in Alzheimer’s disease.
16:22		605-03-003. Cerebral blood flow decline in neurodegeneration using a healthy reference normative model Mathijs Dijsselhof, David Van Nederpelt, Wibeke Nordhøy, Ole Andreassen, Lars Westlye, Luigi Lorenzini, Leo Pieperhoff, Alle Meije Wink, Floor Duits, Alun Hughes, Jonathan Schott, Menno Schoonheim, Eva Strijbis, Joost Kuijer, Bert-Jan Van den Born, Mervin Tee, Saima Hilal, Christopher Chen, Frederik Barkhof, James Cole, Jan Petr, Henk Mutsaerts Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands Impact: Charting healthy reference life-course cerebral blood flow (CBF) and its deviations in cerebrovascular and neurodegenerative pathology will aid in developing early (cerebro)vascular-based diagnosis and personalised preventative and treatment strategies, advancing CBF as a non-invasive generalisable physiological cerebrovascular biomarker.
16:33		605-03-004. Dynamic Deuterium Metabolic Imaging in Patients with Alzheimer’s Disease at 3T: Initial Feasibility Study Yang Fan, Jialu Zhang, Jinxia Guo, Chunsheng Wang, Rolf Schulte, Bing Wu, Feng Chen GE Healthcare, Beijing, China Impact: Dynamic DMI at 3T enables time‑resolved mapping of cerebral glucose metabolism in Alzheimer’s disease patients. This pilot study establishes feasibility and highlights potential for a radiation‑free biomarker to monitor neurodegeneration and therapeutic response.
16:44		605-03-005. Glial metabolic alterations in an Alzheimer’s disease model with selective ApoE4-to-ApoE2 switching in the brain Tamara Vasilkovska, Aditya Jhajharia, Xiao Gao, Georgios Batsios, Minjie Zhu, Lesley Golden, Georgia Nolt, Ken Nakamura, Pavithra Viswanath, Lance Johnson, Jeremy Gordon University Of California, San Francisco (UCSF), United States of America Impact: This study shows the potential of using hyperpolarized (HP) ¹³C MRI to investigate in-vivo, in real-time metabolic alterations in Alzheimer’s disease (AD). Importantly, this work shows the application of HP ¹³C MRI in understanding cell-specific therapeutic strategies in AD.
16:55		605-03-006. Limbic Neurometabolic Network Segregation Underlies Cognitive Resilience in Alzheimer’s Disease Wenli Li, Miao Zhang, Yibo Zhao, Yudu Li, Wen Jin, Yaoyu Zhang, Yue Guan, Wenqi Zhang, Zhi-Pei Liang, Yao Li Shanghai Jiao Tong University, Shanghai, China Impact: Neurometabolic network segregation within the limbic system underlies cognitive resilience in AD. Preserved neuronal network organization may buffer against glucose hypometabolism, offer potential biomarkers and provide targets for interventions aimed at maintaining cognition despite AD pathology.
17:06		605-03-007. Clinically feasible SANDI MRI for early identification of neurodegeneration in Alzheimer’s disease Hansol Lee, Jeremy Ford, Kwok-Shing Chan, Hong Hsi Lee, Susie Huang Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Charlestown, United States of America Impact: Clinical SANDI enables early, noninvasive detection of AD-related microstructural changes using clinically feasible multi-shell diffusion MRI. Its high sensitivity and clinical applicability highlight its practical utility, with strong translational potential to advance understanding of AD pathophysiology and its clinical implications.
17:17		605-03-008. Direct Myelin Imaging as a Novel Biomarker Across the Alzheimer Disease Spectrum Jinil Park, Sam Sedaghat, Brittany Dugger, Eddie Fu, Kader Oguz, Youngkyoo Jung, Fang Liu, Hyungseok Jang University of California, Berkeley, United States of America Impact: This work demonstrates Inversion Recovery Ultrashort Echo Time (IR-UTE) MRI technique to assess myelin integrity in human post-mortem brain tissues. This provides a feasible imaging biomarker to assess demyelination, a critical early event in Alzheimer disease, and track its progression.
17:28		605-03-009. Gradient Echo with Improved Microstructure-Informed Myelin, Iron and Water Mapping predicts Cognitive Decline in Aging and AD MANXI XU, Mert Sisman, Aocai Yang, Yian Gao, Peiling Ou, Pascal Spincemaille , Guolin Ma, Yi Wang China-Japan Friendship Hospital, Beijing, China Impact: This study highlights iMIMM's ability to noninvasively detect white matter changes like myelin loss, iron alterations, and edema in cognitive decline, offering potential biomarkers for early AD detection and personalized interventions, advancing MRI-based neurological assessments.
17:39		605-03-010. Quantitative Susceptibility Mapping Detects Neuroinflammation-Driven Changes Across the Alzheimer’s Disease Continuum Seyyed Ali Hosseini, Nesrine Rahmouni, Stijn Servaes, Arthur C. Macedo, Tevy Chan, Brandon Hall, Hangwei Zhuang, Junghun Cho, Sanjeev Chawla, Yi Wang, Pedro Rosa‐Neto McGill University, Montreal, Canada Impact: QSM identifies neuroinflammation-linked magnetic susceptibility alterations independent of amyloid and tau pathology. These findings provide a clinically practical, radiation-free biomarker to evaluate disease-modifying therapies targeting iron dysregulation and microglial activation in Alzheimer’s disease.